Embecta Corp.

FRC's fair value estimate for Embecta Corp., and the rating behind it. EMBC last traded at $4.94, 3.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Embecta Corp.. Starting points for Embecta Corp.: P/E 3.3, EPS $1.50, beta 0.85 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Embecta Corp.. Embecta Corp. paid $0.32 per share over the last year — a 6.5% yield at the current $4.94 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Embecta Corp.. Trailing twelve-month EPS for Embecta Corp. stands at $1.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Embecta Corp.. Embecta Corp. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Embecta Corp. valued side by side against its closest peers. Embecta Corp. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Embecta Corp., and how their positions are changing. At a $293.1M market value, institutional positions materially move Embecta Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Embecta Corp. executives and directors. Shares of Embecta Corp. have traded between $9.20 and $21.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Embecta Corp.. Embecta Corp. is a $293.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Embecta Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Embecta Corp.. Coverage tracks Embecta Corp. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.